Sponsors / TRVI
TRVI

Trevi Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
10Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusNCT02143648Trevi TherapeuticsPhase 2, Phase 3Completed2015-07Actual
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusNCT02143973Trevi TherapeuticsPhase 2, Phase 3Completed2016-01Actual
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisNCT02174419Trevi TherapeuticsPhase 2, Phase 3Completed2016-08Actual
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisNCT02174432Trevi TherapeuticsPhase 2, Phase 3Completed2017-09-03Actual
PRISM Study-Pruritus Relief Through Itch Scratch ModulationNCT03497975Trevi TherapeuticsPhase 2, Phase 3Completed2022-05-10Actual
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughNCT04030026Trevi TherapeuticsPhase 2Completed2022-05-27Actual
Refractory Chronic Cough Improvement Via NAL ER (RIVER)NCT05962151Trevi TherapeuticsPhase 2Completed2025-01-06Actual
Cough Reduction in IPF With Nalbuphine ERNCT05964335Trevi TherapeuticsPhase 2Completed2025-04-24Actual
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsNCT07671911Trevi TherapeuticsPhase 3Recruiting2028-06Estimated
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)NCT07671924Trevi TherapeuticsPhase 2Recruiting2027-09Estimated

Latest recorded trial changes